Suven Life Sciences

SUVEN · NSE · India

Public Market Listing

SUVENNSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Suven Life Sciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Serotonin 5-HT6 receptorSmall molecule
Alzheimer's Disease
Phase 2
Alpha4beta2 nicotinic acetylcholine receptorSmall molecule
Major Depressive Disorder

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MasupirdinePhase 3Agitation, Alzheimer's Type Dementia
Est. primary completion 2026-12 · NCT05397639 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$2.4M$33M—$31Mreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.1M$20M—$19Mreport ↗
2024-FY—$17M—$13Mreport ↗
2023-FY$2.7M——$15Mreport ↗